- Home
- CGEM vs SAFE Comparison
CGEM vs SAFE Comparison
Compare CGEM & SAFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | SAFE |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.4M | 847.7M |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CGEM | SAFE |
|---|---|---|
| Price | $12.92 | $11.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $33.45 | $16.44 |
| AVG Volume (30 Days) | ★ 1.2M | 647.9K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 6.13% |
| EPS Growth | N/A | ★ 7.43 |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $385,552,000.00 |
| Revenue This Year | N/A | $12.10 |
| Revenue Next Year | $280.38 | $4.57 |
| P/E Ratio | ★ N/A | $14.09 |
| Revenue Growth | N/A | ★ 5.43 |
| 52 Week Low | $6.73 | $11.48 |
| 52 Week High | $23.19 | $17.45 |
Technical Indicators
Market Signals| Indicator | CGEM | SAFE |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 22.01 |
| Support Level | $11.87 | N/A |
| Resistance Level | $13.21 | $16.43 |
| Average True Range (ATR) | 0.91 | 0.30 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 0.64 | 7.98 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.